BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team ...

BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will ...

(MENAFN- GlobeNewsWire - Nasdaq) BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has received a consensus rating of “Buy” from the five analysts that are presently covering the firm, Marketbeat reports.

Corvus Pharmaceuticals, Inc. - GlobeNewswire - Tue Feb 4, 7:00AM CST BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on ...